✦ LIBER ✦

4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial

✍ Scribed by Hoskin, Peter J; Kirkwood, Amy A; Popova, Bilyana; Smith, Paul; Robinson, Martin; Gallop-Evans, Eve; Coltart, Stewart; Illidge, Timothy; Madhavan, Krishnaswamy; Brammer, Caroline; Diez, Patricia; Jack, Andrew; Syndikus, Isabel

Book ID: 122133015
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 214 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(14)70036-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reduced-intensity chemotherapy and PET-g

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

✍ Andreas Engert; Heinz Haverkamp; Carsten Kobe; Jana Markova; Christoph Renner; A 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 327 KB

High-dose methotrexate with or without w

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

✍ Eckhard Thiel; Agnieszka Korfel; Peter Martus; Lothar Kanz; Frank Griesinger; Mi 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 377 KB

Bendamustine plus rituximab versus CHOP

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

✍ Rummel, Mathias J; Niederle, Norbert; Maschmeyer, Georg; Banat, G Andre; von Grü 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 312 KB

S-1 plus oxaliplatin versus capecitabine

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial

✍ Yong Sang Hong; Young Suk Park; Ho Yeong Lim; Jeeyun Lee; Tae Won Kim; Kyu-pyo K 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 200 KB

Efficacy and safety of 12-weekly versus

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

✍ Amadori, Dino; Aglietta, Massimo; Alessi, Barbara; Gianni, Lorenzo; Ibrahim, Ton 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 265 KB